Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel Disease

Journal of Crohn's and Colitis

Volumn 5, Issue 5, 2011, Pages 484-498

  Daperno, Marco ^a   Castiglione, Fabiana ^b   de Ridder, Lissy ^c   Dotan, Iris ^d   Färkkilä, Martti ^e   Florholmen, Jon ^f   Fraser, Gerald ^d   Fries, Walter ^g   Hebuterne, Xavier ^h   Lakatos, Peter Laszlo ⁱ   Panés, Julián ^j   Rimola, Jordi ^j   Louis, Edouard ^k  

^a MAURIZIANO HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF HELSINKI   (Finland)

^f UNIVERSITY OF TROMSØ   (Norway)

^g UNIVERSITY OF MESSINA   (Italy)

^h UNIVERSITY HOSPITAL OF NICE   (France)

ⁱ SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^j INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^k UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

Endoscopy; Fecal markers; Genetic markers; Imaging techniques; Inflammatory bowel disease; Mucosal healing; Serologic markers; Transmural healing

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; CORTISONE; INFLIXIMAB; MESALAZINE; OUTER MEMBRANE PROTEIN C; SALAZOSULFAPYRIDINE;

CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CROHN DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE SYSTEM DISEASE; DISEASE MARKER; DRUG WITHDRAWAL; ENDOSCOPIC THERAPY; ENDOSCOPY; ENTERITIS; FECES ANALYSIS; GENETIC MARKER; HUMAN; INTESTINE ENDOSCOPY; INTESTINE MUCOSA; INTESTINE ULCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; ULCER HEALING; ULCERATIVE COLITIS; WORKSHOP;

BIOLOGICAL MARKERS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MAGNETIC RESONANCE IMAGING; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WOUND HEALING;

EID: 80053130162     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.003     Document Type: Review

References (150)

1. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
2. Daperno M., D'Haens G., Van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
3. Cellier C., Sahmoud T., Froguel E., Adenis A., Belaiche J., Bretagne J.F., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994, 35:231-235.
4. Rutgeerts P., Geboes K., Vantrappen G., Kerremans R., Coenegrachts J.L., Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984, 25:665-672.
5. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
6. Ardizzone S., Maconi G., Sampietro G.M., Russo A., Radice E., Colombo E., et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004, 127:730-740.
7. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723-729.
8. Marteau P., Lemann M., Seksik P., Laharie D., Colombel J.F., Bouhnik Y., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842-847.
9. Reinisch W., Angelberger S., Petritsch W., Shonova O., Lukas M., Bar-Meir S., et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 2010, 59:752-759.
10. Colombel J.F., Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn's disease treated with certolizumab Pegol: first results of the MUSIC clinical trial. Am J Gastroenterol 2008, 103:1107. (A).
11. Louis E., Vernier-Massouille G., Grimaud J., Bouhnik Y., Laharie D., Dupas J.L., et al. Infliximab discontinuation in Crohn's disease patients in stable remission of combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008, 57:A66. (OP302).
12. Reinisch W., Rutgeerts P., Panaccione R., D'Haens G., Thakkar R., Yu A., et al. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab-treated patients with Crohn's disease. J Crohns Colitis 2010, 4:P045.
13. Baert F., Moortgat L., Van Assche G., Caenepeel P., Vergauwe P., De Vos M., et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010, 138:463-468. quiz e10-1.
14. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006, 63:433-442. quiz 464.
15. Rutgeerts P., D'Haens G., Van Assche G., Sandborn W.J., Wolf D.C., Colombel J.F., et al. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohn's disease: first results of the EXTEND trial. Gastroenterology 2009, 136:A751.
16. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
17. Calabrese E., Petruzziello C., Onali S., Condino G., Zorzi F., Pallone F., et al. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm Bowel Dis 2009, 15:1635-1642.
18. Sailer J., Peloschek P., Reinisch W., Vogelsang H., Turetschek K., Schima W. Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol 2008, 18:2512-2521.
19. Rutgeerts P., Thakkar R., Kaltenboeck A., Li Z., Yang M., Chao J., et al. Mucosal healing predicts long-term clinical benefits for adalimumab-treated patients with Crohn's disease. J Crohns Colitis 2010, 4:S37.
20. Bourreille A., Ignjatovic A., Aabakken L., Loftus E.V., Eliakim R., Pennazio M., et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009, 41:618-637.
21. Efthymiou A., Viazis N., Mantzaris G., Papadimitriou N., Tzourmakliotis D., Raptis S., et al. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm Bowel Dis 2008, 14:1542-1547.
22. Echarri A., Castro J., Barreiro M., Carpio D., Pereira S., Lorenzo A. Evaluation of adalimumab therapy in multidisciplinary strategy for perianal Crohn's disease patients with infliximab failure. J Crohns Colitis 2010, 4:654-660.
23. Gonzalez-Lama Y., Abreu L., Vera M.I., Pastrana M., Tabernero S., Revilla J., et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis 2005, 11:8-15.
24. Karmiris K., Bielen D., Vanbeckevoort D., Vermeire S., Coremans G., Rutgeerts P., et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011, 9:130-136.
25. Van Assche G., Vanbeckevoort D., Bielen D., Coremans G., Aerden I., Noman M., et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 2003, 98:332-339.
26. Florie J., Horsthuis K., Hommes D.W., Nio C.Y., Reitsma J.B., van Deventer S.J., et al. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3:1221-1228.
27. Parisinos C.A., McIntyre V.E., Heron T., Subedi D., Arnott I.D., Mowat C., et al. Magnetic resonance follow-through imaging for evaluation of disease activity in ileal Crohn's disease: an observational, retrospective cohort study. Inflamm Bowel Dis 2010, 16:1219-1226.
28. Parmentier-Decrucq E., Duhamel A., Ernst O., Fermont C., Louvet A., Vernier-Massouille G., et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. Inflamm Bowel Dis 2009, 15:1476-1484.
29. Rimola J., Ordas I., Rodriguez S., Panes J. Colonic Crohn's disease: value of magnetic resonance colonography for detection and quantification of disease activity. Abdom Imaging 2010, 35:422-427.
30. Rimola J., Rodriguez S., Garcia-Bosch O., Ordas I., Ayala E., Aceituno M., et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009, 58:1113-1120.
31. Girlich C., Ott C., Strauch U., Schacherer D., Obermeier F., Jung E.M., et al. Clinical feature and bowel ultrasound in Crohn's disease - does additional information from magnetic resonance imaging affect therapeutic approach and when does extended diagnostic investigation make sense?. Digestion 2011, 83:18-23.
32. Horsthuis K., Bipat S., Bennink R.J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008, 247:64-79.
33. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041-1048.
34. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1964, 1:89-92.
35. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978, 13:971-976.
36. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625-1629.
37. Bitton A., Peppercorn M.A., Antonioli D.A., Niles J.L., Shah S., Bousvaros A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
38. Ohkusa T., Kato K., Terao S., Chiba T., Mabe K., Murakami K., et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 2010, 105:1820-1829.
39. Riley S.A., Mani V., Goodman M.J., Herd M.E., Dutt S., Turnberg L.A. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988, 94:1383-1389.
40. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
41. Sandborn W.J., Tremaine W.J., Leighton J.A., Lawson G.M., Zins B.J., Compton R.F., et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 1997, 11:663-671.
42. Sandborn W.J., Tremaine W.J., Schroeder K.W., Batts K.P., Lawson G.M., Steiner B.L., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994, 106:1429-1435.
43. Van Assche G., Sandborn W.J., Feagan B.G., Salzberg B.A., Silvers D., Monroe P.S., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 2006, 55:1568-1574.
44. Osada T., Ohkusa T., Yokoyama T., Shibuya T., Sakamoto N., Beppu K., et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm Bowel Dis 2010, 16:192-197.
45. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
46. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005, 352:2499-2507.
47. Thia K.T., Loftus E.V., Pardi D.S., Kane S.V., Faubion W.A., Tremaine W.J., Schroeder K.W., Harmsen S.W., Zinsmeister A.R., Sandborn W.J. Measurement of disease activity in ulcerative colitis: interobserver agreement and predictors of severity. Inflamm Bowel Dis 2011, 17:1257-1264.
48. Samuel S., Loftus E.V., Bruining D.H., Thia K.T., Tremaine W.J., Schroeder K.W., et al. Validation of the ulcerative colitis endoscopic index of severity (UCEIS) and its correlation with clinical indices and laboratory measures of disease activity. Gastroenterology 2011, 140:A851.
49. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 133:412-422.
50. Solberg I.C., Lygren I., Jahnsen J., Aadland E., Høie O., Cvancarova M., et al. Clinical course during the first 10years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440.
51. Meucci G., Fasoli R., Saibeni S., Valpiani D., Gullotta R., Colombo E., et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results from a prospective, multicenter study. Gastroenterology 2006, 130:A197.
52. Ardizzone S., Cassinotti A., Duca P., Mazzali C., Penati C., Manes G., Marmo R., Massari A., Molteni P., Maconi G., Porro G.B. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2011, 9:483-489.
53. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
54. Pineton de Chambrun G., Peyrin-Biroulet L., Lemann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
55. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
56. Louis E., Ancion G., Colard A., Spote V., Belaiche J., Hustinx R. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 2007, 48:1053-1059.
57. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R., et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002, 8:244-250.
58. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr El Yafi F.A., Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001, 49:777-782.
59. Oussalah A., Laurent V., Bruot O., Bressenot A., Bigard M.A., Regent D., et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut 2010, 59:1056-1065.
60. Castiglione F., de Sio I., Cozzolino A., Rispo A., Manguso F., Del Vecchio Blanco G., et al. Bowel wall thickness at abdominal ultrasound and the one-year-risk of surgery in patients with Crohn's disease. Am J Gastroenterol 2004, 99:1977-1983.
61. Maconi G., Carsana L., Fociani P., Sampietro G.M., Ardizzone S., Cristaldi M., et al. Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features. Aliment Pharmacol Ther 2003, 18:749-756.
62. Maconi G., Parente F., Bollani S., Cesana B., Bianchi Porro G. Abdominal ultrasound in the assessment of extent and activity of Crohn's disease: clinical significance and implication of bowel wall thickening. Am J Gastroenterol 1996, 91:1604-1609.
63. Parente F., Maconi G., Bollani S., Anderloni A., Sampietro G., Cristaldi M., et al. Bowel ultrasound in assessment of Crohn's disease and detection of related small bowel strictures: a prospective comparative study versus x ray and intraoperative findings. Gut 2002, 50:490-495.
64. Rigazio C., Ercole E., Laudi C., Daperno M., Lavagna A., Crocella L., et al. Abdominal bowel ultrasound can predict the risk of surgery in Crohn's disease: proposal of an ultrasonographic score. Scand J Gastroenterol 2009, 44:585-593.
65. Fraquelli M., Sarno A., Girelli C., Laudi C., Buscarini E., Villa C., et al. Reproducibility of bowel ultrasonography in the evaluation of Crohn's disease. Dig Liver Dis 2008, 40:860-866.
66. Bernstein C.N., Greenberg H., Boult I., Chubey S., Leblanc C., Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am J Gastroenterol 2005, 100:2493-2502.
67. Bruining D.H., Siddiki H.A., Fletcher J.G., Tremaine W.J., Sandborn W.J., Loftus E.V. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm Bowel Dis 2008, 14:1701-1706.
68. Lee S.S., Kim A.Y., Yang S.K., Chung J.W., Kim S.Y., Park S.H., et al. Crohn disease of the small bowel: comparison of CT enterography, MR enterography, and small-bowel follow-through as diagnostic techniques. Radiology 2009, 251:751-761.
69. Desmond A.N., O'Regan K., Curran C., McWilliams S., Fitzgerald T., Maher M.M., et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 2008, 57:1524-1529.
70. Herfarth H., Palmer L. Risk of radiation and choice of imaging. Dig Dis 2009, 27:278-284.
71. Levi Z., Fraser E., Krongrad R., Hazazi R., benjaminov O., meyerovitch J., et al. Factors associated with radiation exposure in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 30:1128-1136.
72. Peloquin J.M., Pardi D.S., Sandborn W.J., Fletcher J.G., McCollough C.H., Schueler B.A., et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 2008, 103:2015-2022.
73. Biancone L., Schillaci O., Capoccetti F., Bozzi R.M., Fina D., Petruzziello C., et al. Technetium-99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am J Gastroenterol 2005, 100:344-354.
74. Sciarretta G., Furno A., Mazzoni M., Basile C., Malaguti P. Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut 1993, 34:1364-1369.
75. Stathaki M.I., Koukouraki S.I., Karkavitsas N.S., Koutroubakis I.E. Role of scintigraphy in inflammatory bowel disease. World J Gastroenterol 2009, 15:2693-2700.
76. Rispo A., Imbriaco M., Celentano L., Cozzolino A., Camera L., Mainenti P.P., et al. Noninvasive diagnosis of small bowel Crohn's disease: combined use of bowel sonography and Tc-99m-HMPAO leukocyte scintigraphy. Inflamm Bowel Dis 2005, 11:376-382.
77. Charron M., del Rosario F.J., Kocoshis S.A. Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology 1999, 212:507-513.
78. Charron M., Di Lorenzo C., Kocoshis S. Are 99mTc leukocyte scintigraphy and SBFT studies useful in children suspected of having inflammatory bowel disease?. Am J Gastroenterol 2000, 95:1208-1212.
79. Cucchiara S., Celentano L., de Magistris T.M., Montisci A., Iula V.D., Fecarotta S. Colonoscopy and technetium-99m white cell scan in children with suspected inflammatory bowel disease. J Pediatr 1999, 135:727-732.
80. Lemberg D.A., Issenman R.M., Cawdron R., Green T., Mernagh J., Skehan S.J., et al. Positron emission tomography in the investigation of pediatric inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:733-738.
81. Loffler M., Weckesser M., Franzius C., Schober O., Zimmer K.P. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 2006, 1072:379-385.
82. Neurath M.F., Vehling D., Schunk K., Holtmann M., Brockmann H., Helisch A., et al. Noninvasive assessment of Crohn's disease activity: a comparison of 18F-fluorodeoxyglucose positron emission tomography, hydromagnetic resonance imaging, and granulocyte scintigraphy with labeled antibodies. Am J Gastroenterol 2002, 97:1978-1985.
83. Ahmadi A., Li Q., Muller K., Collins D., Valentine J.F., Drane W., et al. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm Bowel Dis 2010, 16:974-981.
84. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
85. Van Assche G., Dignass A., Panes J., Beaugerie L., Karagiannis J., Allez M., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010, 4:7-27.
86. Gasche C., Moser G., Turetschek K., Schober E., Moeschl P., Oberhuber G. Transabdominal bowel sonography for the detection of intestinal complications in Crohn's disease. Gut 1999, 44:112-117.
87. Negaard A., Paulsen V., Sandvik L., Berstad A.E., Borthne A., Try K., et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis. Eur Radiol 2007, 17:2294-2301.
88. Solem C.A., Loftus E.V., Fletcher J.G., Baron T.H., Gostout C.J., Petersen B.T., et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008, 68:255-266.
89. Voderholzer W.A., Beinhoelzl J., Rogalla P., Murrer S., Schachschal G., Lochs H., et al. Small bowel involvement in Crohn's disease: a prospective comparison of wireless capsule endoscopy and computed tomography enteroclysis. Gut 2005, 54:369-373.
90. Vogel J., da Luz Moreira A., Baker M., Hammel J., Einstein D., Stocchi L., et al. CT enterography for Crohn's disease: accurate preoperative diagnostic imaging. Dis Colon Rectum 2007, 50:1761-1769.
91. Maccioni F., Bruni A., Viscido A., Colaiacomo M.C., Cocco A., Montesani C., et al. MR imaging in patients with Crohn disease: value of T2- versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology 2006, 238:517-530.
92. Pilleul F., Godefroy C., Yzebe-Beziat D., Dugougeat-Pilleul F., Lachaux A., Valette P.J. Magnetic resonance imaging in Crohn's disease. Gastroenterol Clin Biol 2005, 29:803-808.
93. Toma P., Granata C., Magnano G., Barabino A. CT and MRI of paediatric Crohn disease. Pediatr Radiol 2007, 37:1083-1092.
94. van Gemert-Horsthuis K., Florie J., Hommes D.W., Lavini C., Reitsma J.B., van Deventer S.J., et al. Feasibility of evaluating Crohn's disease activity at 3.0 Tesla. J Magn Reson Imaging 2006, 24:340-348.
95. Potthast S., Rieber A., Von Tirpitz C., Wruk D., Adler G., Brambs H.J. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002, 12:1416-1422.
96. Schmidt S., Lepori D., Meuwly J.Y., Duvoisin B., Meuli R., Michetti P., et al. Prospective comparison of MR enteroclysis with multidetector spiral-CT enteroclysis: interobserver agreement and sensitivity by means of "sign-by-sign" correlation. Eur Radiol 2003, 13:1303-1311.
97. Gourtsoyiannis N.C., Grammatikakis J., Papamastorakis G., Koutroumbakis J., Prassopoulos P., Rousomoustakaki M., et al. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur Radiol 2006, 16:1915-1925.
98. Masselli G., Casciani E., Polettini E., Lanciotti S., Bertini L., Gualdi G. Assessment of Crohn's disease in the small bowel: prospective comparison of magnetic resonance enteroclysis with conventional enteroclysis. Eur Radiol 2006, 16:2817-2827.
99. Martinez M.J., Ripolles T., Paredes J.M., Blanc E., Marti-Bonmati L. Assessment of the extension and the inflammatory activity in Crohn's disease: comparison of ultrasound and MRI. Abdom Imaging 2009, 34:141-148.
100. Spradlin N.M., Wise P.E., Herline A.J., Muldoon R.L., Rosen M., Schwartz D.A. A randomized prospective trial of endoscopic ultrasound to guide combination medical and surgical treatment for Crohn's perianal fistulas. Am J Gastroenterol 2008, 103:2527-2535.
101. Ng S.C., Plamondon S., Gupta A., Burling D., Swatton A., Vaizey C.J., et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009, 104:2973-2986.
102. Ardizzone S., Maconi G., Colombo E., Manzionna G., Bollani S., Bianchi Porro G. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 2004, 10:91-96.
103. Schwartz D.A., White C.M., Wise P.E., Herline A.J. Use of endoscopic ultrasound to guide combination medical and surgical therapy for patients with Crohn's perianal fistulas. Inflamm Bowel Dis 2005, 11:727-732.
104. Ahmad T., Armuzzi A., Bunce M., Mulcahy-Hawes K., Marshall S.E., Orchard T.R., et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002, 122:854-866.
105. Lakatos P.L., Lakatos L., Szalay F., Willheim-Polli C., Osterreicher C., Tulassay Z., et al. Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol 2005, 11:1489-1495.
106. Weersma R.K., Stokkers P.C., van Bodegraven A.A., van Hogezand R.A., Verspaget H.W., de Jong D.J., et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009, 58:388-395.
107. Henckaerts L., Van Steen K., Verstreken I., Cleynen I., Franke A., Schreiber S., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 7:972-980. e2.
108. Papp M., Koromi Z., Davida L., Altorjay I., Palatka K., Udvardy M., et al. Formation of antiphospholipid antibodies (APLA) is associated to the presence of anti-Saccharomyces cerevisiae antibodies (ASCA) in inflammatory bowel disease. J Crohns Colitis 2011, 5:S165.
109. Desir B., Amre D.K., Lu S.E., Ohman-Strickland P., Dubinsky M., Fisher R., et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:139-146.
110. Rieder F., Schleder S., Wolf A., Dirmeier A., Strauch U., Obermeier F., et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis 2010, 16:1367-1375.
111. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 2006, 131:366-378.
112. Ferrante M., Henckaerts L., Joossens M., Pierik M., Joossens S., Dotan N., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
113. Papp M., Altorjay I., Dotan N., Palatka K., Foldi I., Tumpek J., et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol 2008, 103:665-681.
114. Seow C.H., Stempak J.M., Xu W., Lan H., Griffiths A.M., Greenberg G.R., et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009, 104:1426-1434.
115. Forcione D.G., Rosen M.J., Kisiel J.B., Sands B.E. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004, 53:1117-1122.
116. Papp M., Altorjay I., Norman G.L., Shums Z., Palatka K., Vitalis Z., et al. Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients. Inflamm Bowel Dis 2007, 13:984-992.
117. Vasiliauskas E.A., Kam L.Y., Karp L.C., Gaiennie J., Yang H., Targan S.R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
118. Amre D.K., Lu S.E., Costea F., Seidman E.G. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006, 101:645-652.
119. Dubinsky M.C., Kugathasan S., Mei L., Picornell Y., Nebel J., Wrobel I., et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008, 6:1105-1111.
120. Esters N., Vermeire S., Joossens S., Noman M., Louis E., Belaiche J., et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002, 97:1458-1462.
121. Teml A., Kratzer V., Schneider B., Lochs H., Norman G.L., Gangl A., et al. Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol 2003, 98:2226-2231.
122. Ashorn S., Raukola H., Valineva T., Ashorn M., Wei B., Braun J., et al. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J Clin Immunol 2008, 28:486-494.
123. Papp M., Foldi I., Altorjay I., Palyu E., Udvardy M., Tumpek J., et al. Anti-microbial antibodies in celiac disease: trick or treat?. World J Gastroenterol 2009, 15:3891-3900.
124. Jones J., Loftus E.V., Panaccione R., Chen L.S., Peterson S., McConnell J., et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008, 6:1218-1224.
125. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Vavricka S.R., Bruegger L.E., et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162-169.
126. Sipponen T., Karkkainen P., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008, 28:1221-1229.
127. Canani R.B., Terrin G., Rapacciuolo L., Miele E., Siani M.C., Puzone C., et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008, 40:547-553.
128. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
129. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Renzulli P., Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
130. Xiang J.Y., Ouyang Q., Li G.D., Xiao N.P. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008, 14:53-57.
131. D'Inca R., Dal Pont E., Di Leo V., Ferronato A., Fries W., Vettorato M.G., et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007, 22:429-437.
132. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14:40-46.
133. Sipponen T., Savilahti E., Karkkainen P., Kolho K.L., Nuutinen H., Turunen U., et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008, 14:1392-1398.
134. Kaiser T., Langhorst J., Wittkowski H., Becker K., Friedrich A.W., Rueffer A., et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007, 56:1706-1713.
135. Moum B., Jahnsen J., Bernklev T. Fecal calprotectin variability in Crohn's disease. Inflamm Bowel Dis 2010, 16:1091-1092.
136. Gomes P., du Boulay C., Smith C.L., Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986, 27:92-95.
137. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
138. Osada T., Ohkusa T., Okayasu I., Yoshida T., Hirai S., Beppu K., et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol 2008, 23(Suppl 2):S262-S267.
139. Henriksen M., Jahnsen J., Lygren I., Stray N., Sauar J., Vatn M.H., et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008, 57:1518-1523.
140. Futterman L.G., Lemberg L. High-sensitivity C-reactive protein is the most effective prognostic measurement of acute coronary events. Am J Crit Care 2002, 11:482-486.
141. Colombel J.F., Solem C.A., Sandborn W.J., Booya F., Loftus E.V., Harmsen W.S., et al. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006, 55:1561-1567.
142. Cui G., Olsen T., Christiansen I., Vonen B., Florholmen J., Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand J Clin Lab Invest 2006, 66:249-259.
143. Schmidt C., Giese T., Hermann E., Zeuzem S., Meuer S.C., Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007, 13:65-70.
144. Olsen T., Goll R., Cui G., Christiansen I., Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 2009, 46:222-227.
145. Arsenescu R., Bruno M.E., Rogier E.W., Stefka A.T., McMahan A.E., Wright T.B., et al. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol 2008, 1:399-411.
146. Ishiguro Y. Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis. J Gastroenterol 1999, 34:66-74.
147. Raddatz D., Bockemuhl M., Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005, 17:547-557.
148. Arijs I., Li K., Toedter G., Quintens R., Van Lommel L., Van Steen K., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 58:1612-1619.
149. Marchesi J.R., Holmes E., Khan F., Kochhar S., Scanlan P., Shanahan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007, 6:546-551.
150. Manfredi M.A., Zurakowski D., Rufo P.A., Walker T.R., Fox V.L., Moses M.A. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:1091-1096.